Lunsumio (mosunetuzumab-axgb) and Lunsumio Velo (mosunetuzumab-axgb) - Coverage Criteria
Customize your policy alerts
Sign up for Anthem Policy CC-0232 alerts
Get alerted when Policy CC-0232 changes without checking for updates manually.
Monitor payer policy activity
Clinical criteria and coding guidance governing prior authorization and coverage considerations for Lunsumio (IV) and Lunsumio Velo (SC) for treatment of relapsed/refractory follicular lymphoma and certain NCCN 2A B-cell lymphoma indications; applies to Anthem medical benefit reviews.
Added Lunsumio Velo to criteria and to HCPCS J9350 and added ICD-10-CM C83.10-C83.19.
Updated criteria to include new NCCN 2A recommended use with Polivy for Mantle Cell Lymphoma and use as combination therapy with polatuzumab-vedotin-piiq for second-line+ therapy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.